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 The aim of this study was to clarify whether or not pre-
operative serum levels of sialyl Lewisa (CA19-9), sialyl 
LewisX (SLX), and sialyl Tn (STN) antigens are predictors 
for diffuse type gastric cancer. Eighty-two patients with 
diffuse type and 96 patients with intestinal type cancers 
were studied. Univariate logistic regression analysis showed 
that the following factors were significantly associated 
with diffuse type cancer: high levels of serum STN, young 
age (<62 years), female gender, tumor in the middle stom-
ach, macroscopic type 3/type 4 cancer, presence of lym-
phatic invasion, peritoneal dissemination, stage III/IV, and 
non-curative resection. Multivariate analysis revealed that 
diffuse type cancer was independently related to young age 
(<62 years), female gender, tumor in the middle stomach, 
and macroscopic type 3/type 4 cancer. In conclusion, none 
of the preoperative serum levels of CA19-9, SLX, and STN 
were predictors for diffuse type cancer. 
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Introduction
 Gastric cancer has been divided histologically into 
an intestinal type and a diffuse type' 2' . There has 
been a dramatic and unexplained decrease in the inci-
dence of gastric cancer, and this has occurred primar-
ily in the intestinal type. However, unless gastric can-
cer is identified early, the prognosis for cure remains 
poor''. The diffuse type gastric cancer has been associ 
ated with a poorer prognosis than the intestinal type'-".
Therefore, preoperative prediction of diffuse type gas-
tric cancer is important to establish strategies for peri-
operative adjuvant chemotherapy. 
 Sialyl Lewisa (CA 19-9), sialyl Lewisx (SLX), and 
sialyl Tn antigen (STN) antigens are among the 
mucin-associated carbohydrate moieties found in large 
quantities in gastric tumors'). CA 19-9 and SLX repre-
sent examples of type 1 and type 2 terminal carbohy-
drate structures, respectively. STN is an example of a 
carbohydrate core structure". These three antigens 
may play an important role in cell adhesion. Their 
key role in local tumor invasiveness and metastasis 
has been previously discussed"'). These carbohydrate 
antigens have also been detected in the sera of gastric 
cancer patients"'). Thus far, a correlation has been re-
ported between serum levels of carbohydrate antigens 
and diffuse or intestinal type gastric cancer'-"'. 
However, in these reports, clinical and pathological 
data were evaluated only by univariate analysis. We 
believe that the results of univariate analysis should 
be confirmed by multivariate analysis. 
 In this study, we examined the preoperative serum 
levels of CA 19-9, SLX, and STN in gastric cancer pa-
tients who underwent gastrectomy. The aim of this 
study was to clarify whether or not the serum levels 
of these carbohydrate antigens are predictors for dif-
fuse type gastric cancer. We also evaluated the serum 
CEA levels in the same patients with gastric cancer 
because CEA is commonly used to evaluate recurrence 
and prognosis of gastric cancer patients after surgery".
Patients and Methods
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Patients
 A total of 178 gastric cancer patients (120 males 
and 58 females) were included in this study. The me-
dian age of patients was 62.0 years (range, 29 to 86
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years). All patients underwent resection for a gastric 
tumor at Nagasaki University Hospital and Sasebo 
Municipal Hospital between 1991 and 1993. Patients 
who had a synchronous or metachronous cancer of 
the stomach were excluded from this study. None of 
the patients had any evidence of other organ malig-
nancies or history of preoperative treatment with anti-
cancer drugs. 
 The following standardized procedures were per-
formed: (i) gastric resection (the gastric resection line 
was 3 cm from the macroscopic edge for localized tu-
mors and 5 cm for infiltrating tumors); (ii) prophylac-
tic lymph node dissection greater than removal of 
group 1 lymph nodes"); and (iii) complete excision of 
invaded organs, irrespective of the number of sites on 
the organs, provided that there was no evidence of in-
curable factors such as peritoneal dissemination, liver 
metastasis, and widespread nodal involvement"'. One 
hundred-twenty three patients underwent partial 
gastrectomy, and 55 patients had a total gastrectomy. 
The number of patients who underwent curative re-
section was 153. Twenty-five patients had noncurative 
resection. None of the patients died within 30 postop-
erative days. Written informed consent was obtained 
from each patient. At the time these data were ana-
lyzed, the median follow-up was 61.5 months (range: 
42 days to 154.6 months).
Intestinal and diffuse types gastric cancer
 Pathologic diagnoses and classification of the 
resected gastric cancer tissues were made according to 
the Japanese Classification of Gastric Carcinomal3' 
The histological classification was determined based 
on the predominant pattern of tumor as follows: papil-
lary adenocarcinoma, tubular adenocarcinoma, poorly 
differentiated adenocarcinoma, signet-ring cell carci-
noma, and mucinous carcinoma. Papillary or tubular 
adenocarcinoma can be interpreted as intestinal type, 
whereas poorly differentiated adenocarcinoma or sig-
net-ring cell carcinoma can be regarded as diffuse 
type. Mucinous carcinoma can be interpreted as either 
intestinal or diffuse type, depending upon other pre-
dominant elements (papillary adenocarcinoma, tubular 
adenocarcinoma, poorly differentiated adenocarcinoma, 
or signet-ring cell carcinoma)"'.
Serum levels of CA19-9, SLX, STN, and CEA were 
measured by the Otsuka Assay Laboratory (Tokushima, 
Japan) using the following commercially available 
radioimmunoassay kits: the Centocor CA 19-9 RIA kit 
(Centocor, Malvern, PA, USA)"), the FH-6 "Otsuka" kit 
(Otsuka Assay Lab., Tokushima, Japan)'6' , the STN 
"Otsuka" kit (Otsuka Assay Lab ., Tokushima, Japan)"), 
and the CEA Roche 2 kit (Nippon Roche K.K., Tokyo, 
Japan)"), respectively. The data obtained were based 
on simultaneous assays for each antigen using the 
same set of sera. According to the manufacturers' in-
structions, the diagnostic cut-off values for each 
marker were 37 U/ml for CA19-9, 38 U/ml for SLX, 
45 U/ml for STN, and 2.5 ng/ml for CEA1-'$'. We 
classified patients into two groups based on the serum 
levels of each antigen: a high antigen group, serum 
antigen concentration greater than the recommended 
cut-off value; and a low antigen group, concentrations 
less than the cut-off value.
Statistical analysis
 Logistic regression analysis was chosen to study the 
predictive value of risk factors because the outcome 
variable was binary (intestinal type cancer versus dif-
fuse type cancer)'" O'. Potentially predictive variables 
were identified using a significance level of P<0.25 by 
univariate analysis, and these variables were then 
used in multivariate analysis. A 25% significance level 
was selected based on the recommendations of Hosmer 
and Lemeshow for building multivariate models20'. 
 Two variables with continuous data, such as age 
and maximal tumor diameter, were classified in two 
groups based on the median values (62.0 years and 4.0 
cm, respectively). The disease-specific interval was cal-
culated according to the Kaplan-Meier method 211 , and 
differences between disease-specific intervals were 
tested for significance using the log rank test22' 
 All tests were two-tailed and a P value of less than 
0.05 was considered significant.
Results
 Of the 178 gastric cancers, 96 (53.9%) were classified 
as intestinal type cancers and 82 (46.1%) were classi-
fied as diffuse type cancers.
Measurement of the serum levels of antigens
 To detect the presence of circulating cancer mark-
ers, venous blood was obtained from patients after an 
overnight fast. Blood samples were immediately sepa-
rated by centrifugation and sera were stored at -80'C.
Comparison of disease-specific survival after gastrectomy 
between patients with intestinal type cancer and those 
with diffuse type cancer 
 The survival time of patients with diffuse type
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cancer was significantly shorter than the survival 
time of patients with intestinal type cancer (P=0.035) 
(Fig. 1). The cumulative 5-year survival rates were as 
follows: 59.8% among patients with diffuse type can-
cer, and 74.2% among patients with intestinal type 
cancer.
Time after surgery (years)
Figure 1. Comparison of disease-specific survival between 
patients with intestinal type cancer and those with diffuse 
type cancers of the stomach.
Logistic regression analysis to determine the predictive 
factors for diffuse type cancer
 As shown in Table 1, 18 variables were included in 
this analysis. Univariate analysis showed that the fol-
lowing ten variables were significantly associated with 
diffuse type cancer: age, gender, tumor location, mac-
roscopic type, serosal invasion, lymphatic invasion, 
peritoneal dissemination, stage, operative curability, 
and serum STN status. 
 To avoid the problem of collinearity in multivariate 
analysis, the variables 'stage' and 'operative curability' 
were excluded. By means of univariate analysis, 11 
variables (age, gender, maximum tumor diameter, 
tumor location, macroscopic type, serosal invasion, 
lymphatic invasion, venous invasion, lymph node me-
tastasis, peritoneal dissemination, and serum STN 
status) were identified at a significance level of P<0.25 
for diffuse type cancer. These variables were therefore 
included in the multivariate analysis. Consequently, 
the diffuse type cancer was found to be independently 
related to four variables: young age (<62 years), fe-
male gender, tumor located in the middle stomach, 
and macroscopic type 3 or type 4 cancer. Of note, 
serum STN status was not related with diffuse type 
gastric cancer.
Table 1. Logistic regression analysis of predictive vari-
ables for diffuse type gastric cancer.
                          Univariate Multivariate 
                          analysis analysis
Variables OR (95% CI)* P value OR (95% Cl)* P value 
Age 
 a62 years (n=95) 1 1 
 <62 years (n=83) 3.29 (1.77-6.11) 0.0002 3.83 (1.71-8.60) 0.0010 
Gender 
 Male (n=120) 1 1 
 Female (n=58) 5.25 (2.62-10.51) <0.0001 4.75 (2.05-11.02) 0.0003 
Maximum tumor diameter 
 <4.0 cm (n=87) 1 1 
 z4.0 cm (n=91) 1.74 (0.96-3.17) 0.068 1.56 (0.57-4.29) 0.38 
Tumor location 
 Lower stomach (n=63) 1 1 
 Middle stomach (n=77) 2.40 (1.20-4.80) 0.013 3.15 (1.28-7.76) 0.012 
 Upper stomach (n=38) 2.00 (0.87-4.58) 0.099 2.13 (1.73-6.17) 0.16 
Macroscopic type 
 Type 0 (n=77) 1 1 
 Type 1 or Type 2 (n=47) 1.20 (0.56-2.59) 0.64 2.52 (0.70-9.07) 0.15 
 Type 3 or Type 4 (n=54) 6.21 (2.86-13.49) <0.0001 6.65 (1.46-30.30) 0.013 
Serosal invasion 
 Absent (n=127) 1 1 
 Present (n=51) 2.59 (1.32-5.09) 0.0053 1.85 (0.61-5.56) 0.27 
Lymphatic invasion 
 Absent (n=74) 1 1 
 Present (n=104) 2.15 (1.16-4.00) 0.014 0.85 (0.29-2.58) 0.78 
Venous invasion 
 Absent (n=120) 1 1 
 Present (n=58) 1.72 (0.91-3.26) 0.092 0.72 (0.25-2.03) 0.53 
Lymph node metastasis 
 Absent (n=94) 1 1 
 Present (n=84) 1.78 (0.98-3.24) 0.059 0.67 (0.23-1.90) 0.45 
Peritoneal dissemination 
 Absent (n=164) 1 1 
 Present (n=14) 4.80 (1.28-18.03) 0.019 2.32 (0.38-14.10) 0.36 
Liver metastasis 
 Absent (n=166) 1 
 Present (n=12) 0.82 (0.25-2.73) 0.75 
Stage 
 
I (n=92) 1 
 II (n=21) 1.55 (0.59-4.06) 0.37 
 III (n=35) 2.27 (1.02-5.05) 0.042 
 IV (n=30) 2.56 (1.09-5.98) 0.029 
Operative procedures 
 Partial gastrectomy (123) 1 
 Total gastrectomy (n=55) 1.32 (0.70-2.51) 0.39 
Operative curabilityt 
 Curative (n=153) 1 
 Noncurative (n=25) 2.55 (1.37-4.75) 0.0030
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Serum CA19-9 status 
 Low CA19-9group (n=141) 1 
 High CA19-9 group (n=37) 0.75 (0.36-1.58) 0.45 
Serum SLX status 
 Low SLX group (n=147) 1 
 High SLX group (n=31) 1.12 (0.51-2.44) 0.78 
Serum STN status 
 Low STN group (n=150) I 1 
 High STN group (n=28) 2.42 (1.04-5.62) 0.039 1.25 (0.37-4.31) 0.72 
Serum CEA status 
 Low CEA group (n=146) 1 
 High CEA group (n=32) 0.76 (0.35-1.67) 0.50 
"` OR, odds ratio; CI, confidence interval. 
( In accordance with the criteria of the Japanese research Society for gastric carcinoma ]';).
Discussion
  In order to improve upon clinicopathological correla-
tion, Lauren divided gastric cancer into intestinal and 
diffuse types"". The intestinal type has distinct large 
glands that are usually lined by well-polarized colum-
nar cells with a well-developed brushed border. In the 
diffuse type of gastric cancer, the glandular structure 
is rarely present, and cells are scattered either as soli-
tary cells or small clusters of cells. Typically, the in-
testinal type is better circumscribed than the diffuse 
type 1, 2 , 13) The intestinal type gastric cancer appears 
to show a preference for liver metastasis, whereas the 
diffuse type is more likely to metastasize to the peri-
toneum and lymph nodes'-". The diffuse type gastric 
cancer has been associated with a poorer prognosis 
than the intestinal type"'. The current study also re-
vealed concordant results; i.e., the survival time of pa-
tients with diffuse type cancer was significantly 
shorter than the survival time of patients with intesti-
nal type cancer. 
 In order to establish the strategy of preoperative 
(neoadjuvant) and/or postoperative adjuvant chemo-
therapy, a useful tumor marker that is able to predict 
diffuse type gastric cancer would be necessary. Thus 
far, no correlation between serum levels of CA 19-9 or 
SLX and the Lauren's classification been reported'-"'. 
Our current results were concordant with the results 
of their previous study. The current study revealed no 
correlation between serum CEA levels and Lauren's 
classification. However, Kodera et al.") reported that 
high serum CEA levels had a tendency to be associ-
ated with the intestinal type of gastric cancer 
(P=0.085). Kodama et al."' also reported a significant 
association between high serum CEA levels and the 
intestinal type of cancer. However, this result was
based on a small number of patients with gastric can-
cer (6 intestinal and 40 diffuse type cancers). Thus, al-
though high serum levels of CEA appear to be associ-
ated with the intestinal type of gastric cancer, these 
studies were evaluated by univariate analysis. The re-
sults of univariate analysis should be confirmed by 
multivariate analysis in a large number of patients. 
 Takahashi et al.") reported no significant correlation 
between serum STN levels and the diffuse or intesti-
nal type of gastric cancers. In the current study, the 
univariate analysis demonstrated that among the four 
carbohydrate antigens (CA 19-9, SLX, STN, and CEA), 
only high serum levels of STN was significantly asso-
ciated with diffuse type cancer. However, the multi-
variate analysis showed that the level of serum STN 
was not an independent predictor for diffuse type. 
 Some studies reported that immunohistochemical ex-
pression of STN did not significantly correlate with 
Lauren's classification (the intestinal or diffuse type 
cancer)"-"'. However, some reports have revealed that 
the intestinal type of cancers express STN more often 
than diffuse type cancers.","). Thus, the correlation be-
tween STN expression and Lauren's classification is 
controversial. Ikeda et al."' reported that the spread of 
STN into the surrounding stroma in diffuse type can-
cer may be associated with peritoneal dissemination in 
Stage IV gastric cancer. We previously reported that 
preoperative serum levels of STN predict liver metas-
tasis and poor prognosis in patients with gastric can-
cer. However, the high serum levels of STN was asso-
ciated with the diffuse type cancer"). Based on these 
results, we speculate that STN may not correlate with 
Lauren's classification (the intestinal or diffuse type c 
ancer), even though STN has an important role in 
metastasis of gastric cancer. 
 Body fluid (particularly blood and urine) testing for 
molecular markers (biomarkers) is easily accessible 
and useful in patients. The prognostic significance of 
circulating DNA in plasma or serum, and its genetic 
alterations in cancer are important trends"'. In the 
current study, among the four carbohydrate antigens 
(CA 19-9, SLX, STN, and CEA), we could not find an 
independent marker that predicted for the diffuse type 
gastric cancer. Further study using biomarkers is 
needed to clarify this issue.
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